HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reckitt's OTC Sales Slide 40% In 'Exceptionally Weak' Cold & Flu Season

Executive Summary

Reckitt reports major drop in OTC sales in Q1 as the cold and flu season was almost wiped out by social distancing measures related to COVID-19. CEO Laxman Narasimhan reveals he has seen green shoots in certain markets where restrictions have started to relax, insisting "there is no question flu will come back."

You may also be interested in...



Euro Q2 Earnings Preview: GSK, Sanofi, Bayer And Reckitt

Major Europe-based consumer health players GSK, Sanofi, Bayer and Reckitt are all hoping for a sales boost in Q2 following a difficult Q1 due to the almost non-existent cough and cold season. This earnings preview highlights what to look out for as these four firms report their second-quarter results over the coming weeks.

RB Doubles R&D Spend In Search Of 'Game Changing’ OTC Innovation

With Reckitt's OTC sales falling 3% in 2020, the firm has committed to doubling its R&D spend in search of breakthrough product innovations.

Reckitt Reports Strongest Quarter In 20 Years Driven By 50% E-commerce Sales Jump

Consumers' significant shift to buying more health products online likely is a permanent trend, says RB CEO Laxman Narasimhan. A 37.4% jump in North America on health product stockpiling drove 13.6% growth in global health business sales.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS151272

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel